Quell Therapeutics expands Series A financing to $84 million
London, UK-based cell therapy specialist Quell Therapeutics today announced the closing of an extended Series A financing led by its existing investors Syncona, which has committed an additional $34.7 million and UCL Technology Fund (UCLTF), which has committed an additional $1 million; bringing the total Series A financing to circa $84 million.
Quell is funded to progress its program in liver transplantation to clinical proof of concept, whilst expanding its portfolio into autoimmune and neuroinflammatory diseases. Additionally, the funding will allow the company to further develop scalable manufacturing processes and expand its senior leadership team.
Lead program QEL-001 set to enter clinic in 1st-half 2022
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze